RICHMOND, British Columbia, Oct. 6, 2005 (PRIMEZONE) -- BioCurex Inc. (Pink Sheets:BOCX) is pleased to advise its shareholders and investors that they can access a Corporate update on the News section of BioCurex's website at www.biocurex.com.
As a result of frequent discussions with shareholders, the Company wishes to discuss several specific issues of importance:
-- The current state of our technology. -- The size and scope of our targeted markets. -- A discussion of our financing procedures. -- Pink Sheets and alternative listing -- Investor Relations -- Investment Banking -- Our Conclusions
The Company continues to progress in many areas and is committed to periodic updates for its shareholders. We are very pleased with the support shown by our investors as we advance deliberately and successfully towards our corporate goals.
About BioCurex:
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To read more about the Company, please visit the News section in our web site (www.biocurex.com).
Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.